Skip to content
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Day: September 3, 2024

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More
Page1 Page2 Page3
RECENT POSTS

Ebola Outbreak in Eastern DR Congo Claims Over 300 Children; New Vaccine Trials Recommended

August 7, 2026

DR Congo Ebola Outbreak Surpasses 4,000 Cases Amidst Expanding Health Response

August 7, 2026

Ebola Cases Surpass 4,000 in Democratic Republic of Congo

August 7, 2026

Antwerp Confronts Colonial Past with Monument to Human Zoo Victims

August 7, 2026

Ebola Death Toll Tops 1,800 in DRC

August 7, 2026

DRCs Largest Ebola Outbreak on Record: Active Conflict and Armed Groups Hamper the Response

August 7, 2026

Nigeria Slashes Malaria Burden To 15 Pct Over 15 Years

August 6, 2026

At Least 308 Kidnapped Victims Rescued In Nigerian Military Operation

August 6, 2026
Copyright © 2026 Le Congo Tribune. All Rights Reserved.